Celera and Abbott Collaborate To Identify Pharmacogenomic Markers

(Alameda, CA, USA) has entered into a collaborative research agreement with Abbott Labs (Abbott Park, IL, USA) to identify genetic markers for one of Abbot's investigational compounds. A major goal of this collaboration is to investigate if genetic variants Celera has identified can predict how patients may respond to treatment. The identification of treatment response markers may assist in further development of a drug.

Under the terms of this collaboration, Abbott will pay Celera an undisclosed fee to perform this study and any resulting companion diagnostic product could be developed by Celera and commercialized through its existing strategic alliance with Abbott.

"We're pleased to enter this collaboration with Abbott as it further reinforces Celera's commitment to personalized medicine,” said Thomas White, Ph.D., chief scientific officer at Celera. "The results of this study will provide new information on the correlation between genetic markers associated with disease and response to therapy. Routinely testing this general concept in early clinical trials may give us new and important insights to personalizing disease management.”

Celera is a healthcare business that provides personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and the company has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases.

Abbott Labs is a diversified pharmaceuticals healthcare company that discovers, develops, manufactures, and sells pharmaceutical and nutritional products such as drug delivery systems, antibiotics, and prepared infant formulas.

Related Links:
Celera
Abbott Labs